Consensus Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Market Closed - Nasdaq Other stock markets 01:30:01 02/05/2024 am IST			5-day change	1st Jan Change
19 ^USD	+5.94%		+17.97%	+73.72%

23/04	Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	MT
22/04	RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	MT

Evolution of the average Target Price on Edgewise Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

48d.4osDX9Pxbl9j12DeECBxtZuTz9verkPzyqmF5NLWZug.u-ltaOamBRBQug63emkbgcOniraY5HGSp_7ur6W0LLHSslUxops7Fg20Ew~f74ec7f1b8c40f4ded98c0bc0bb9132e

Analyst Recommendations on Edgewise Therapeutics, Inc.

RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	22/04	MT
Piper Sandler Starts Edgewise Therapeutics With Overweight Rating, $48 Price Target	07/03	MT
Wedbush Raises Edgewise Therapeutics' PT to $26 From $23, Continues to See 2024 as Critical Year; Keeps Outperform Rating	23/02	MT
Wedbush Lowers Edgewise Therapeutics' PT to $23 From $27, Sees 2024 as 'Critical' Year; Keeps Outperform Rating	10/11	MT
JPMorgan Adjusts Price Target on Edgewise Therapeutics to $25 From $24, Maintains Overweight Rating	30/23/30	MT
JPMorgan Adjusts Price Target on Edgewise Therapeutics to $24 From $25, Maintains Overweight Rating	16/23/16	MT
Truist Securities Starts Edgewise Therapeutics at Buy With $25 Price Target	01/23/01	MT
Wedbush Trims Edgewise Therapeutics' Price Target to $27 From $28 After Minor Adjustments to Estimates, Keeps Outperform Rating	24/23/24	MT
RBC Cuts Price Target on Edgewise Therapeutics to $29 From $31, Maintains Outperform, Speculative Risk Rating	04/22/04	MT
Wedbush Adjusts Edgewise Therapeutics Price Target to $28 From $31, Maintains Outperform Rating	03/22/03	MT
Goldman Sachs Downgrades Edgewise Therapeutics to Sell From Neutral, Keeps $5 Price Target	25/22/25	MT
Goldman Sachs Adjusts Edgewise Therapeutics' Price Target to $5 from $8, Keeps Neutral Rating	24/22/24	MT
JPMorgan Adjusts Price Target for Edgewise Therapeutics to $28 From $32, Maintains Overweight Rating	24/22/24	MT
Goldman Sachs Adjusts Price Target for Edgewise Therapeutics to $8 From $11, Maintains Neutral Rating	12/22/12	MT
SVB Securities Adjusts Edgewise Therapeutics' Price Target to $30 from $34, Keeps Outperform Rating	12/22/12	MT
RBC Initiates Edgewise Therapeutics at Outperform, Speculative Risk With $31 Price Target, Bullish on '5506 Treatment for Muscular Dystrophies	13/22/13	MT
JPMorgan Adjusts Edgewise Therapeutics' Price Target to $32 from $33, Maintains Overweight Rating	14/22/14	MT
Goldman Sachs Starts Edgewise Therapeutics at Neutral With $11 Price Target	28/22/28	MT
JPMorgan Adjusts Edgewise Therapeutics' Price Target to $33 from $30, Keeps Overweight Rating	06/22/06	MT
JPMorgan Adjusts Edgewise Therapeutics' Price Target to $30 From $35, Reiterates Overweight Rating	02/21/02	MT
EDGEWISE THERAPEUTICS : Wedbush Adjusts Price Target on Edgewise Therapeutics to $31 From $35, Keeps Outperform Rating	10/21/10	MT
EDGEWISE THERAPEUTICS : Wedbush Adjusts Price Target on Edgewise Therapeutics to $35 From $38, Keeps Outperform Rating	14/21/14	MT
EDGEWISE THERAPEUTICS : JP Morgan Initiates Edgewise Therapeutics at Overweight Rating With $34 Price Target	20/21/20	MT
EDGEWISE THERAPEUTICS : SVB Leerink Starts Edgewise Therapeutics at Outperform With $34 Price Target	20/21/20	MT
EDGEWISE THERAPEUTICS : Wedbush Starts Edgewise Therapeutics at Outperform With $38 Price Target	20/21/20	MT